Form 4: Phio Pharmaceuticals CEO Acquires Additional Shares
SEC Form 4 Filing
Robert J. Bitterman, President & CEO of Phio Pharmaceuticals Corp., purchased 1,000 shares of common stock at $0.75 per share on June 6, 2024.
Summary
- On June 6, 2024, Robert J. Bitterman, the President & CEO of Phio Pharmaceuticals Corp., acquired 1,000 shares of common stock.
- The purchase price was $0.75 per share.
- Following the transaction, Bitterman directly owns 19,990 shares of Phio Pharmaceuticals Corp., which includes shares of common stock underlying unvested restricted stock units.
Sentiment
Score: 5
Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is slightly positive as insider buying can be seen as a good sign, but it's a small transaction.
Positives
- The CEO's purchase of shares may signal confidence in the company's future prospects.
Industry Context
Insider trading activity is often monitored as an indicator of a company's health and future performance, though it is not always indicative of future results.
Stakeholder Impact
- The stock purchase could have a minor positive impact on shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of the stock purchase transaction. |
| 06/10/2024 | Date of signature on the Form 4 filing. |
Keywords
Phio Pharmaceuticals, Robert Bitterman, insider trading, stock purchase, Form 4, CEO, ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.